Built on Insight
We believe every cancer patient deserves the right treatment the first time. At AIDA, we’re building the tools to make that possible.
AIDA was founded by practicing oncologists who have witnessed firsthand the devastating impact of cancer and the frustration of uncertain treatment outcomes. This gives us a unique understanding of the challenges clinicians face and what is truly needed to improve patient treatment. This deep personal insight drives us every day to develop precision tools that empower doctors and give patients the best chance of receiving effective, personalized therapy.
Cancer is complex.
So is our science.
But our insights are clear.
At AIDA, we combine RNA expression, machine learning, and clinical data to deliver personalized cancer treatment. Our predictors analyze each patient’s unique tumor biology to identify the treatments most likely to help and those to avoid.
By moving beyond one-size-fits-all protocols, we aim to double response rates and improve cure rates through optimized drug selection and therapy sequencing.
Our mission is simple but ambitious.
Ensure every patient starts with the treatment most likely to improve outcomes and help minimize harm, reducing uncertainty from day one. By using data to guide decisions, we’re not just focused on improving survival, we are building a future where cancer treatment is precise and personal.
Our Values
Data-Driven Insight
We listen carefully to patients, clinicians and caregivers. With medical experts and frontline experience on our team, we bring empathy and clinical insight to everything we build, creating tools that truly enable better treatment outcomes.
Precision for Every Individual
Every patient’s cancer is different. Our work is grounded in the promise of consistently delivering the right therapy for each individual patient.
Patient-Centered
We build technology with the patient at the core, designed to improve outcomes, reduce unnecessary side effects, and enhance the treatment journey.
Our integrative approach enables us to successfully develop robust panels of predictors designed to assess patient responses to commonly used chemotherapies.